Sagent Pharmaceuticals and Qilu Team Up to Enhance U.S. Access to Injectable Medicines

Sagent Pharmaceuticals and Qilu Collaborate for Injectable Innovations



In an impressive stride towards ensuring a more robust healthcare framework, Sagent Pharmaceuticals and Qilu Pharmaceutical Co., Ltd. have recently announced a strategic partnership aimed at enhancing the availability of critical injectable products in the U.S. market. This collaboration holds the potential to address significant patient needs while emphasizing the commitment of both companies to improve overall healthcare access.

Partnership Highlights


The partnership establishes Sagent Pharmaceuticals as the exclusive commercial agent for a carefully curated portfolio of Qilu's complex injectable products in the U.S. market. These products target high-impact therapeutic areas, addressing unmet patient needs in the American healthcare landscape, thereby filling a crucial gap in medication accessibility.

The total addressable market for these injectable products is projected to exceed a remarkable $4.5 billion. This figure not only illustrates the vast demand for these therapies but also highlights the critical role both companies play in meeting healthcare needs and reducing treatment costs across a diverse range of services.

Leadership Insights


Dr. Vishy Chebrol, the CEO of Sagent, stated that the collaboration marks a vital milestone in their mission to build a strong and varied pharmaceutical portfolio within the U.S. market. He expressed great enthusiasm about working alongside Qilu, emphasizing the importance of providing high-value, clinically essential therapies to ensure they reach the patients who rely on them the most.

On the other hand, Hanchang Zhang, Vice President of Qilu Pharmaceutical Group, shared his satisfaction regarding this collaboration. He noted that this partnership reflects Qilu's dedication to making high-quality, effective medicines affordable for patients worldwide. With Qilu's advanced development and manufacturing capabilities in conjunction with Sagent's strong commercial platform and agile market approach, both entities look forward to advancing patient care and reinforcing a reliable pharmaceutical supply chain.

About Sagent Pharmaceuticals


Established in 2006, Sagent Pharmaceuticals has quickly risen to prominence as a provider of generic and specialty pharmaceuticals. With a diversified portfolio of over 100 products, Sagent caters to various therapeutic categories by offering multiple formulations and packaging options, thereby adapting to the dynamic requirements of patients. Their global network fosters rapid development and innovative drug delivery technologies aligning with the evolving needs of the healthcare sector.

You can learn more about their initiative in injectables at Sagent Pharmaceuticals.

About Qilu Pharmaceutical


Founded in 1958, Qilu Pharmaceutical has become one of China’s leading vertically integrated pharmaceutical companies, developing, manufacturing, and distributing both Finished Dosage Forms and Active Pharmaceutical Ingredients. With a vast network of 12 subsidiaries and over 36,000 employees, Qilu ranks among the top three in the Chinese pharmaceutical industry as of 2024. The company is recognized for its commitment to quality and innovation, having established a significant international presence by exporting to more than 100 countries. Currently, Qilu holds 39 approved Abbreviated New Drug Applications (ANDAs) in the U.S., with an expansive pipeline that includes over 200 generic products, 20 biosimilars, and 80 innovative products.

Their collaborative efforts with Sagent are set to generate a meaningful impact on patient healthcare accessibility, driving forward their mission of delivering reliable, high-quality medicines to patients worldwide.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.